As previously reported, Truist analyst Asthika Goonewardene downgraded TCR2 Therapeutics (TCRR) to Hold from Buy with a price target of $3, down from $8, after the company entered into a definitive merger agreement under which Adaptimmune (ADAP) will combine with TCR2 in an all-stock transaction. Truist would have liked to have seen TCR2 shares get a better premium in the swap, but thinks the deal provides a way to pivot to a cell therapy name that also embraces the T-cell Receptor, but is closer to commercialization, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRR:
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune downgraded to Hold from Buy at JonesResearch
- Adaptimmune Craters after Acquiring TCRR
- Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors